| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC0448 |
| Trial ID | NCT03614858 |
| Disease | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD20 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. |
| Year | 2017 |
| Country | China |
| Company sponsor | Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd |
| Other ID(s) | UnicarTherapy201807 |
| Cohort1: Tandem CAR-T | |||||||||||||||
|
|||||||||||||||
| Cohort2: Sequential CAR-T | |||||||||||||||
|
|||||||||||||||